摘要
目的观察钻孔尿激酶注入联合阿托伐他汀钙对慢性硬膜下血肿患者术后神经功能恢复的影响及对患者预后相关因子影响。方法选取2014年1月至2016年12月就诊的230例患者,根据随机的原则分为对照组和研究组,每组115例。对照组给予患者钻孔引流治疗,研究组给予患者钻孔尿激酶联合阿托伐他汀钙治疗,观察2组患者的术后神经功能状况及其预后因素中临床疗效、血肿清除率、血肿复发率及并发症的发生情况。结果治疗前2组患者的性别比、年龄、病程、神经功能状态、血肿程度经比较差异无统计学意义(P> 0. 05);治疗后2组患者的神经功能状况较治疗前比较,差异有统计学意义(P <0. 01);治疗后研究组患者的神经功能状态、临床疗效、血肿清除率、血肿复发率及并发症的发生情况均明显优于对照组,差异有统计学意义(P <0. 05)。结论钻孔尿激酶注入联合阿托伐他汀钙治疗慢性硬膜下血肿患者术后神经功能恢复及其预后因素中临床疗效、血肿清除率、血肿复发率及并发症的发生情况影响意义重大,为个人、家庭及社会的健康可持续发展助力,值得临床进一步推广应用。
Objective To observe the effects of drilling urokinase injection combined with atorvastatin calcium on nerve function in postoperative patients with chronic subdural hematoma and prognosis. Methods A total of 230 patients, who were treated in our hospital from January 2014 to December 2016, were randomly divided into control group （ n =115） and research group （ n =115）. The patients in control group were treated by trepanation ＆ drainage. And the patients in reseach group were treated by drilling ＆ urokinase combined with atorvastatin calcium. The neurological functional status after surgery, clinical effect, hematoma clearance rate, recurrence rate and incidence of complications were observed and compared between the two groups. Results Before treatment, there were no significant differences in patient’s sex and age, disease course, neurological functional status and hematoma degree between the two groups （ P 〉0.05）. After treatment, the neurological functional status, clinical effect, hematoma clearance rate, recurrence rate and incidence of complications of the patients in research group were supior to those in control group （ P 〈0.05）. Moreover, there was significant difference in the neurological functional status of the patients before and after treatment （ P 〈0.01）. Conclusion Drilling urokinase injection combined with atorvastatin calcium is very effective in treating the postoperative patients with chronic subdural hematoma,which can significantly improve the neurological functional status of the patients, with better clinical effect, higher hematoma clearance rate, lower recurrence rate and incidence of complications. Thus, it is worthy of clinical promotion.
作者
张蕾
侯梅英
程刚
国义民
ZHANG Lei;HOU Meiying;CHENG Gang(Department of Neurosurgery,The Second People＇s Hospital of Hengshui City,Hebei,Hengshui 053000,China)
出处
《河北医药》
CAS
2018年第20期3137-3140,共4页
Hebei Medical Journal
基金
衡水市科技局计划项目(编号:2016014080Z)
